The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Open accessAbstract
Sclerosteosis is a progressive sclerosing bone dysplasia with an autosomal recessive mode of inheritance. Radiologically, it is characterized by a generalized hyperostosis and sclerosis leading to a markedly thickened and sclerotic skull, with mandible, ribs, clavicles and all long bones also being affected. Due to narrowing of the foramina of the cranial nerves, facial nerve palsy, hearing loss and atrophy of the optic nerves can occur. Sclerosteosis is clinically and radiologically very similar to van Buchem disease, mainly differentiated by hand malformations and a large stature in sclerosteosis patients. By linkage analysis in one extended van Buchem family and two consanguineous sclerosteosis families we previously mapped both disease genes to the same chromosomal 17q12-q21 region, supporting the hypothesis that both conditions are caused by mutations in the same gene. After reducing the disease critical region to approximately 1 Mb, we used the positional cloning strategy to identify the SOST gene, which is mutated in sclerosteosis patients. This new gene encodes a protein with a signal peptide for secretion and a cysteine-knot motif. Two nonsense mutations and one splice site mutation were identified in sclerosteosis patients, but no mutations were found in a fourth sclerosteosis patient nor in the patients from the van Buchem family. As the three disease-causing mutations lead to loss of function of the SOST protein resulting in the formation of massive amounts of normal bone throughout life, the physiological role of SOST is most likely the suppression of bone formation. Therefore, this gene might become an important tool in the development of therapeutic strategies for osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations of this gene can produce the high-bone-mass disorder Van Buchem disease or sclerosteosis”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [73]
Experimental — accuracy not yet measuredIn the citing paper
“Mutations in genes that have highly enriched expression in osteocytes cause rare bone and mineral disorders.”
From Osteocyte transcriptome mapping identifies a molecular landscape controlling skeletal homeostasis and susceptibility to skeletal disease (2021) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pfam Protein Families Database
Bateman, A. G. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.276 · Cited by 14,075
Predicting subcellular localization of proteins based on their N-terminal amino acid sequence.
Emanuelsson, O., Nielsen, H., Brunak, S., & von Heijne, G. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3903 · Cited by 4,419
Shapiro, M. B., & Senapathy, P. (1987) · Nucleic Acids Research · doi:10.1093/nar/15.17.7155 · Cited by 2,313
The Pfam Protein Families Database
Bateman, A. G. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.263 · Cited by 1,262
Crystal structure of human chorionic gonadotropin
Lapthorn, A. J., Harris, D. C., Littlejohn, A. H., Lustbader, J. W., Canfield, R. E., Machin, K. J., Morgan, F. J., & Isaacs, N. W. (1994) · Nature · doi:10.1038/369455a0 · Cited by 933
Hsu, D. R., Economides, A. N., Wang, X., Eimon, P. M., & Harland, R. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80067-2 · Cited by 648
Peer Bork, B. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)80155-n · Cited by 623
The Connective Tissue Growth Factor/Cysteine- Rich 61/Nephroblastoma Overexpressed (CCN) Family
Brigstock, D. R. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.2.0360 · Cited by 588
A structural superfamily of growth factors containing a cystine knot motif
McDonald, N. Q., & Hendrickson, W. A. (1993) · Cell · doi:10.1016/0092-8674(93)90127-c · Cited by 532
Position effect in human genetic disease
Kleinjan, D. A. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.10.1611 · Cited by 370
Research works printed but not linked: 2
- Witkop, C.J. (1965) Genetic diseases of the oral cavity. In Tiecke, R.W. (ed.), Oral Pathology. McGraw-Hill, New York, NY, pp. 834-843.
- Van Buchem, F.S.P., Prick, J.J.G. and Jaspar, H.H.J. (1976) Hyperostosis corticalis generalisata familiaris (van Buchem's disease). In Excerpta Medica. American Elsevier Publishing, New York, NY, pp. 1-205.
Cited by
Sorted by citations
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
Nusse, R., & Clevers, H. (2017) · Cell · doi:10.1016/j.cell.2017.05.016 · Cited by 4,342
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
Manolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,639
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
“Mutations of SOST causes high bone mass in humans,((46)) as does deletion in mice.”
BackgroundRomosozumab Treatment in Postmenopausal Women with Osteoporosis
Cosman, F., Crittenden, D. B., Adachi, J. D., Binkley, N., Czerwinski, E., Ferrari, S., Hofbauer, L. C., Lau, E., Lewiecki, E. M., Miyauchi, A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607948 · Cited by 1,805
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Control of osteoblast function and regulation of bone mass
Harada, S.-I., & Rodan, G. A. (2003) · Nature · doi:10.1038/nature01660 · Cited by 1,478
“Five distinct mutations that lead to SOST inactivation have been identified in families with HBM in South Africa, Senegal, Brazil and the United State”
BackgroundSclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants
Walton, R. T., Christie, K. A., Whittaker, M. N., & Kleinstiver, B. P. (2020) · Science · doi:10.1126/science.aba8853 · Cited by 1,233
Manolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,234
“disorders Van Buchem’s disease and sclerosteosis (91, 92),”
BackgroundBuilding strong bones: molecular regulation of the osteoblast lineage
Long, F. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3254 · Cited by 1,211
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling‐Hampton, K., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,114
Osteocytes, mechanosensing and Wnt signaling
Bonewald, L. F., & Johnson, M. L. (2008) · Bone · doi:10.1016/j.bone.2007.12.224 · Cited by 1,076
“Mutations in Sost and Dkk-1 in humans and/or mice have been shown to result in increased bone mass (10)(9)(111)(84) consistent with a role of the Wnt/βcatenin signaling pathway in bone mass regulation.”
BackgroundLDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling:Arrows point the way
He, X., Semenov, M., Tamai, K., & Zeng, X. (2004) · Development · doi:10.1242/dev.01117 · Cited by 1,044
“Intriguingly, SOST is most related to WISE (38% identical; see Fig.”
BackgroundInfluentialThe Osteocyte: An Endocrine Cell … and More
Dallas, S. L., Prideaux, M., & Bonewald, L. F. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1026 · Cited by 1,042
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Li, X., Ominsky, M. S., Niu, Q., Sun, N., Daugherty, B., D’Agostin, D. M., Kurahara, C., Gao, Y., Cao, J., Gong, J., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080216 · Cited by 941
“Mutations in a previously undescribed gene, SOST, were identified by positional cloning as being responsible for causing sclerosteosis.((3,4)) Sclerostin, the pro-”
Backgroundvan Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L. J. A., de Wilt, E., Karperien, M., Hamersma, H. A., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 893
Osteoblast–osteoclast interactions
Chen, X., Wang, Z., Duan, N., Zhu, G., Schwarz, E. M., & Xie, C. L. (2017) · Connective Tissue Research · doi:10.1080/03008207.2017.1290085 · Cited by 905
“Sclerostin is a protein that is encoded by the SOST gene in humans (52).”
BackgroundBone Morphogenetic Proteins, Their Antagonists, and the Skeleton
CANALIS, E. M., Economides, A. N., & Gazzerro, E. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0023 · Cited by 863
Cellular mechanisms of bone remodeling
Eriksen, E. F. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9153-1 · Cited by 893
“Sclerostin is the product of the SOST gene, which is mutated and downregulated in patients with sclerosteosis and van Buchem disease and sclerosteosis [23], which are diseases characterized by high bone density.”
BackgroundSingle-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G. R., Stouch, B., Fang, L., & Posvar, E. L. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
“Individuals who are homozygous for null mutations in SOST, the gene that encodes sclerostin, have sclerosteosis.((8,9)) This syndrome is characterized by progressive bone thickening that results in significant increases in bone mass and bone mineral density (BMD) throughout the skeleton.”
BackgroundLi, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081206 · Cited by 784
Osteoclast–osteoblast communication
Matsuo, K., & Irie, N. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.027 · Cited by 780
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
Balemans, W., Patel, N., Ebeling, M., Van Hul, E., Wuyts, W., Lacza, C., Dioszegi, M., Dikkers, F. G., Hildering, P., Willems, P. J., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.2.91 · Cited by 698
Self-citationDevelopment of the Endochondral SkeletonPreprint
Long, F., & Ornitz, D. M. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008334 · Cited by 698
“…bone formation, loss-of-function or loss-of-expression mutations in Sost, which are expected to enhance LRP5 signaling, result in the bone-thickening diseases known as sclerosteosis or van Buchem disease, respectively (Balemans et al. 2001, 2002; Brunkow et al. 2001; Staehling-Hampton et al. 2002).”
BackgroundMechanisms of Anabolic Therapies for Osteoporosis
CANALIS, E. M., Giustina, A., & Bilezikian, J. P. (2007) · New England Journal of Medicine · doi:10.1056/nejmra067395 · Cited by 675
Secreted and transmembrane wnt inhibitors and activators
Cruciat, C.-M., & Niehrs, C. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a015081 · Cited by 646
“SOST is highly expressedinosteoblastsandosteocytes, andloss-offunction mutations or down-regulation of SOST are responsible for two rare forms of autosomal recessive severe craniotubular hyperostoses, sclerosteosis (Balemans et al. 2001; Brunkow et al. 2001), and van Buchem disease (Balemans et al.”
BackgroundRole of transforming growth factor-β superfamily signaling pathways in human disease
Gordon, K. J., & Blobe, G. C. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.01.006 · Cited by 664
Bellido, T., Ali, A., Gubrij, I. B., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2005-0239 · Cited by 640
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 648
Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators
Balemans, W., & Hul, W. V. (2002) · Developmental Biology · doi:10.1006/dbio.2002.0779 · Cited by 616
Self-citationSOST is a target gene for PTH in bone
Keller, H., & Kneissel, M. (2005) · Bone · doi:10.1016/j.bone.2005.03.018 · Cited by 618
“This is consistent with reported SOST expression in kidney and cells of the bone-forming lineage [31,47].”
The cell biology of bone metabolism
Datta, H. K., Ng, W. F., Walker, J. A., Tuck, S. P., & Varanasi, S. S. (2008) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.048868 · Cited by 614
Cellular biology of fracture healing
Bahney, C. S., Zondervan, R. L., Allison, P., Theologis, A., Ashley, J. W., Ahn, J., Miclau, T., Marcucio, R. S., & Hankenson, K. D. (2019) · Journal of Orthopaedic Research · doi:10.1002/jor.24170 · Cited by 577
Targeting the Wnt/β-Catenin Pathway to Regulate Bone Formation in the Adult Skeleton
Baron, R., & Rawadi, G. (2007) · Endocrinology · doi:10.1210/en.2007-0270 · Cited by 584
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805133106 · Cited by 556
“Sclerostin is the product of the SOST gene, which is mutated and down-regulated in patients with sclerosteosis and van Buchem’s disease (22, 23).”
BackgroundAging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2011) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 602
“…mutations of the SOST gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth [Balemans et al. 2001], a deletion downstream of this gene, which causes reduced SOST expression, is associated with a milder form of the disorder…”
BackgroundParathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 564
Mechanosensation and transduction in osteocytes
Klein-Nulend, J., Bakker, A. D., Bacabac, R. G., Vatsa, A., & Weinbaum, S. (2013) · Bone · doi:10.1016/j.bone.2012.10.013 · Cited by 528
“tion of sclerosteosis, which is due to a premature termination of the Sost gene [110] that transcribes sclerostin.”
BackgroundDeletion of a Single Allele of the Dkk1 Gene Leads to an Increase in Bone Formation and Bone Mass
Morvan, F., Boulukos, K. E., Clément-Lacroix, P., Roman‐Roman, S., Suc-Royer, I., Vayssière, B., Ammann, P., Martin, P., Pinho, S., Pognonec, P., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060311 · Cited by 533
Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513
Van Wesenbeeck, L., Cleiren, E., Gram, J., Beals, R. K., Bénichou, O., Scopelliti, D., Key, L., Renton, T., Bartels, C., Gong, Y., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/368277 · Cited by 568
“The increased bone formation in sclerosteosis (SOST [MIM 269500]) and in Van Buchem disease (VBCH [MIM 239100]) turned out to be due to loss-of-function mutations of the SOST gene, most likely increasing bone morphogenetic protein signaling (Balemans et al. 2001, 2002; Brunkow et al. 2001).”
BackgroundHellemans, J., Preobrazhenska, O., Willaert, A., Debeer, P., VERDONK, P. C. M., Costa, T., Janssens, K., Menten, B., Roy, N. V., Vermeulen, S. J. T., et al. (2004) · Nature Genetics · doi:10.1038/ng1453 · Cited by 469
“Loss-of-function mutations in SOST , encoding the extracellular BMP antagonist sclerostin, lead to sclerosteosi”
BackgroundTu, X., Rhee, Y., Condon, K. W., Bivi, N., Allen, M. R., Dwyer, D., Stolina, M., Turner, C. H., Robling, A. G., Plotkin, L. I., et al. (2011) · Bone · doi:10.1016/j.bone.2011.10.025 · Cited by 475
“Loss of SOST expression in humans causes the high bone mass disorders Van Buchem’s disease [7] and sclerosteosis [8].”
Lrp5 functions in bone to regulate bone mass
Cui, Y., Niziolek, P., MacDonald, B. T., Diegel, C. R., Alenina, N. V., Robinson, D. R., Zhong, Z. A., Matthes, S., Jacobsen, C. M., Conlon, R. A., et al. (2011) · Nature Medicine · doi:10.1038/nm.2388 · Cited by 460
Role and mechanism of action of sclerostin in bone
Delgado‐Calle, J., Sato, A. Y., & Bellido, T. (2016) · Bone · doi:10.1016/j.bone.2016.10.007 · Cited by 465
“Sclerostin is encoded by Sost, a gene identified through genetic linkage analyses in sclerosteosis and van Buchem’s disease patients (7;32).”
InfluentialGenomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
“An exciting development has been the recent discovery of a novel protein that acts as a negative regulator of bone formation, sclerostin (SOST) (Balemans et al. 2001; Brunkow et al. 2001), whose expression is affected in both sclerosteosis and Van Buchem disease.”
BackgroundInfluentialMechanical Signaling for Bone Modeling and Remodeling
Robling, A. G., & Turner, C. H. (2009) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i4.50 · Cited by 443
“Tanaka S, Sakai A, Tanaka M, Otomo H, Okimoto N, Sakata T, Nakamura T. Skeletal unloading alleviates the anabolic action of intermittent PTH(1-34) in mouse tibia in association with inhibition of PTH-induced increase in c-fos mRNA in bone marrow cells.”
BackgroundOsteocytes as Dynamic Multifunctional Cells
Bonewald, L. F. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.018 · Cited by 457
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G. J., Gong, J., Gao, Y., Cao, J., Graham, K. C., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Sclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 409
Relation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 403
“(1,3–6) The biologic importance of sclerostin in humans is highlighted by sclerosteosis and van Buchem disease, two genetic diseases associated with markedly increased bone mass.(7–10) Sclerosteosis is caused by a mutation in the gene encoding sclerostin, SOST, that leads to improper splicing of the SOSTmRNA,(7,8) whe…”
BackgroundUpdate on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee‐Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2011) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 400
Control of Bone Mass and Remodeling by PTH Receptor Signaling in Osteocytes
O’Brien, C. A., Plotkin, L. I., Galli, C., Goellner, J. J., Gortázar, A. R., Allen, M. R., Robling, A. G., Bouxsein, M., Schipani, E., Turner, C. H., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002942 · Cited by 396
“Loss of sclerostin expression in humans results in the high bone mass disorders Van Buchem’s disease [17] and sclerosteosis [18], providing compelling evidence”
BackgroundOsteocyte-Driven Bone Remodeling
Bellido, T. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9774-y · Cited by 384
“Loss of SOST expression in humans causes the high–bone mass disorders Van Buchem’s disease [16] and sclerosteosis [17].”
Ralston, S. H., & Uitterlinden, A. G. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0044 · Cited by 396
Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
Kitaura, H., Marahleh, A., Ohori, F., Noguchi, T., Shen, W.-R., Qi, J., Nara, Y., Pramusita, A., Kinjo, R., & Mizoguchi, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145169 · Cited by 405
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
van Bezooijen, R. L., ten Dijke, P., Papapoulos, S. E., & Löwik, C. W. G. M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.02.005 · Cited by 371
“expression by RT-PCR was found in several other organs, including cartilage, bone marrow, kidney, heart, aorta, lung, pancreas, skeletal muscle, liver, skin, and placenta [18,19].”
BackgroundInfluentialEsen, E., Chen, J., Karner, C. M., Okunade, A. L., Patterson, B. W., & Long, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.017 · Cited by 367
“Moreover, deficiency in SOST, a secreted inhibitor that prevents the binding of WNT to LRP5 or LRP6, results in high bone mass in human patients (Balemans et al., 2001, 2002).”
BackgroundGenetic regulation of bone mass and susceptibility to osteoporosisPreprint
Ralston, S. H., & Crombrugghe, B. D. (2006) · Genes & Development · doi:10.1101/gad.1449506 · Cited by 370
“1999), and positional cloning studies identified recessive loss-of-function mutations in Sclerostin (SOST) gene as the cause of Sclerosteosis in 2001 (Balemans et al. 2001; Brunkow et al. 2001).”
BackgroundNew sequence variants associated with bone mineral density
Styrkársdóttir, U., Halldórsson, B. V., Grétarsdóttir, S., Gudbjartsson, D. F., Walters, G. B., Ingvarsson, Þ., Jónsdóttir, Þ., Saemundsdottir, J., Snorradóttir, S., Nguyen, T. V., et al. (2008) · Nature Genetics · doi:10.1038/ng.284 · Cited by 361
Bone Morphogenetic Proteins in Vascular Calcification
Hruska, K. A., Mathew, S., & Saab, G. (2005) · Circulation Research · doi:10.1161/01.res.00000175571.53833.6c · Cited by 365
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Wnt signaling in bone formation and its therapeutic potential for bone diseases
Kim, J. H., Liu, X., Wang, J., Chen, X. '., Zhang, H., Kim, S. H., Cui, J., Li, R., Zhang, W., Kong, Y., et al. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12466608 · Cited by 360
“Mutations within the SOST gene were shown to be responsible for sclerosteosis [Balemans et al. 2001], whereas van Buchem’s disease is associated with a 52 kb deletion in the noncoding region containing the enhancer element of SOST [Balemans et al.”
BackgroundBuilding bone to reverse osteoporosis and repair fractures
Khosla, S., Westendorf, J. J., & Oursler, M. J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33612 · Cited by 353
“Sclerostin is the product of the SOST gene, which is mutated and downregulated in patients with sclerosteosis and van Buchem disease (67, 68), diseases characterized by high bone density.”
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 360
Ellies, D. L., Viviano, B. L., McCarthy, J. J., Rey, J., Itasaki, N., Saunders, S., & Krumlauf, R. K. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060810 · Cited by 350
Strontium signaling: Molecular mechanisms and therapeutic implications in osteoporosis
Saidak, Z., & Marie, P. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.009 · Cited by 339
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 345
“In humans, SOST mRNA is expressed in the heart, aorta, and liver, with high levels in the kidney [16, 17, 26, 27]; but no sclerostin protein has”
BackgroundManolagas, S. C., & Almeida, M. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0259 · Cited by 333
Appel, H., Ruiz‐Heiland, G., Listing, J., Zwerina, J., i, M. H., Müeller, R. B., Haibel, H., Baraliakos, X., Hempfing, A., Rudwaleit, M., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24888 · Cited by 326
The BMP signaling and in vivo bone formation
Cao, X., & Chen, D. (2005) · Gene · doi:10.1016/j.gene.2005.06.017 · Cited by 321
A Wnt canon orchestrating osteoblastogenesis
Hartmann, C. (2006) · Trends in Cell Biology · doi:10.1016/j.tcb.2006.01.001 · Cited by 318
Genetics of osteoporosis from genome-wide association studies: advances and challenges
Richards, J. B., Zheng, H., & Spector, T. D. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3228 · Cited by 312
“Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.”
BackgroundMirza, F., Padhi, I. D., Raisz, L. G., & Lorenzo, J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2283 · Cited by 312
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
CANALIS, E. M. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 303
Walker, E. C., McGregor, N. E., Poulton, I. J., Solano, M., Pompolo, S., Fernandes, T. J., Constable, M. J., Nicholson, G. C., Zhang, J., Nicola, N. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40568 · Cited by 302
Bone Overgrowth-associated Mutations in the LRP4 Gene Impair Sclerostin Facilitator Function
Leupin, O., Piters, E., Halleux, C. M., Hu, S., Krämer, I., Morvan, F., Bouwmeester, T., Schirle, M., Bueno-Lozano, M., Fuentes, F. J. R., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190330 · Cited by 304
Staehling‐Hampton, K., Proll, S. C., Paeper, B. W., Zhao, L., Charmley, P., Brown, A., Gardner, J. C., Galas, D. J., Schatzman, R. C., Beighton, P., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10401 · Cited by 294
The role of osteoblasts in energy homeostasis
Dirckx, N., Moorer, M. C., Clemens, T. L., & Riddle, R. C. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0246-y · Cited by 292
A look behind the scenes: the risk and pathogenesis of primary osteoporosis
Hendrickx, G., Boudin, E., & Hul, W. V. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.48 · Cited by 292
Osteocyte RANKL: New insights into the control of bone remodeling
Xiong, J., & O’Brien, C. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1547 · Cited by 295
van Bezooijen, R. L., Svensson, J. P., Eefting, D., Visser, A., van der Horst, G., Karperien, M., Quax, P. H. A., Vrieling, H., Papapoulos, S. E., ten Dijke, P., et al. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061002 · Cited by 286
Osteocytes mediate the anabolic actions of canonical Wnt/β-catenin signaling in bone
Tu, X., Delgado‐Calle, J., Condon, K. W., Maycas, M., Zhang, H., Carlesso, N., Taketo, M. M., Burr, D. B., Plotkin, L. I., & Bellido, T. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409857112 · Cited by 286
Kamiya, N., Ye, L., Kobayashi, T., Mochida, Y., Yamauchi, M., Kronenberg, H. M., Feng, J. Q., & Mishina, Y. M. (2008) · Development · doi:10.1242/dev.025825 · Cited by 279
“Loss-of-function and hypomorphic mutations in SOST cause sclerosteosis (Balemans et al., 2001; Brunkow et al., 2001) and Van Buchem disease (Balemans et al.”
Kusu, N., Laurikkala, J., Imanishi, M., Usui, H., Konishi, M., Miyake, A., Thesleff, I., & Itoh, N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301716200 · Cited by 274
Osteocyte: the unrecognized side of bone tissue
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1194-5 · Cited by 268
“Indeed, mutations in SOST or Dkk1 in humans and in mice lead to an increase in bone mass [110, 117, 137–139].”
Laurikkala, J., Kassai, Y., Pakkasjärvi, L., Thesleff, I., & Itoh, N. (2003) · Developmental Biology · doi:10.1016/j.ydbio.2003.08.011 · Cited by 269
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 281
The osteocyte as a signaling cell
Delgado‐Calle, J., & Bellido, T. (2021) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 280
Ominsky, M. S., Li, C., Li, X., Tan, H. L. E., Lee, E., Barrero, M., Asuncion, F., Dwyer, D., Han, C.-Y. E., Vlasseros, F., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.307 · Cited by 264
Mohammed, M. K., Shao, C. C., Wang, J., Wei, Q., Wang, X. W., Collier, Z. J., Tang, S., Liu, H., Zhang, F., Huang, J., et al. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2015.12.004 · Cited by 266
The WNT system: background and its role in bone
Lerner, U. H., & Ohlsson, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12368 · Cited by 228
Effects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal Women
Drake, M. T., Srinivasan, B., Mödder, U. I., Peterson, J. M., McCready, L. K., Riggs, B. L., Dwyer, D., Stolina, M., Kostenuik, P. J., & Khosla, S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0720 · Cited by 255
Metadata
- Authors
- Balemans, W.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Corresponding author
- Balemans, W.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-03-01
- Volume
- 10
- Issue
- 5
- Pages
- 537-543
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2119934014
- Cited by
- 1,147
- References
- 36
- Citations by year
- 2026: 19 · 2025: 21 · 2024: 34 · 2023: 33 · 2022: 41 · 2021: 64 · 2020: 60 · 2019: 49 · 2018: 48 · 2017: 70 · 2016: 71 · 2015: 74 · 2014: 72 · 2013: 83 · 2012: 68
- FWCI
- 5.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (publishedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- reroDoc Digital Library (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Fonds Wetenschappelijk Onderzoek
- Universiteit Antwerpen
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Dermatological and Skeletal Disorders
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- sclerosteosis, SOST gene, sclerostin, bone mineral density, bone formation regulation, van Buchem disease, positional cloning, nonsense mutation, splice site mutation, loss-of-function mutations, osteoporosis treatment, consanguineous family
- MeSH terms
- Amino Acid Sequence, Base Sequence, Chromosome Mapping, Chromosomes, Human, Pair 17, DNA Mutational Analysis, Genetic Markers, Humans, Genetic Linkage, Molecular Sequence Data, Osteochondrodysplasias, Protein Conformation, Proteins, RNA, Messenger, Bone Density, Sequence Homology, Amino Acid, DNA, Complementary, Bone Morphogenetic Proteins, Adaptor Proteins, Signal Transducing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
